You are here

Artificial Heart Valve Wins FDA Nod

Device reduces complications of valve-replacement procedure

The FDA has approved the SAPIEN 3 transcatheter aortic heart valve for the treatment of high-risk patients with severe, symptomatic aortic stenosis.

The decision was based on positive results from a cohort of the PARTNER II (Placement of AoRTic TraNscathetER Valves II) trial, which enrolled 583 high-risk patients at 29 U.S. sites.

“The PARTNER II study concluded that this new valve reduced several complications associated with the TAVR [transcatheter aortic valve replacement] procedure, such as paravalvular leakage and stroke, and represented a meaningful improvement over data from prior studies with earlier-generation devices,” said co-principal investigator Martin B. Leon, MD, professor of medicine at the Columbia University College of Physicians and Surgeons.

The new valve, available in 20-mm, 23-mm, 26-mm, and 29-mm sizes, has an outer skirt (a cuff of fabric surrounding the valve frame), which provides a seal to address paravalvular leakage, according to its manufacturer, Edwards Lifesciences Corporation. The company expects the product’s launch to be largely completed by the end of the year.

The SAPIEN 3 valve has been commercially available in Europe since January 2014.

Source: Edwards Lifesciences Corp.; June 17, 2015.

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only